Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment;Uveite recidivante di nuova insorgenza in paziente con artrite reumatoide in terapia con anti-TNFα

Reumatismo

Volumn 59, Issue 2, 2007, Pages 169-172

  Di Gangi, M ^a   Foti, Rosario ^a   Leonardi, R ^a   Leonetti, C ^a   Castellino, P ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b Unità Operativa di Medicina Interna   (Italy)

Author keywords

Etanercept; Inflammatory eye disease; Infliximab; Uveitis

Indexed keywords

CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DISEASE ACTIVITY; DISEASE CONTROL; FEMALE; HUMAN; RHEUMATOID ARTHRITIS; UVEITIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MIDDLE AGED; RECURRENT DISEASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 35449005287     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-7.
2. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
3. Monnet D, Moachon L, Dougados M, Brezin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006; 2: 393-7.
4. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003; 87: 925.
5. Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? J Rheumatol 2003; 30: 2727.
6. Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003; 62: 88-9.
7. Rosenbaum JT, Howes EL Jr, Rubin RM, Samples JR. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 1998; 133: 47-53.
8. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R, et al. Acqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophtalmic Res 2001; 33: 251-5.
9. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-84.
10. Rosembaum JT. Blind insight:eyeing anti-tumor necrosis factor treatment in uveitis associated with Behcet's disease. J Rheumatol 2004; 31: 1241-3.
11. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51.
12. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in spondylarthropathy patients: a retrospective study. Ann Rheum Dis 2006; 65: 1631-4.
13. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis Ann Rheum Dis 2006.
14. Kasner L, Chan CC, Whitcup SM, Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993; 34: 2911-7.
15. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 1998; 11: 255-64.
16. Smith JR, Hart PH, Coster DJ, Williams KA. Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1998; 39: 658-861.
17. Marie O, Thillave-Goldenberg B, Naud MC, de Kozak Y. Inhibition of endotoxin-induced uveitis and potentiation of local TNF-alpha and interleukin-6 mRNA expression by interleukin-13. Invest Ophthalmol Vis Sci 1999; 40: 2275-82.
18. Ferguson TA, Griffith TS. The Role of Fas Ligand and TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Ocular Immune Response. Chem Immunol Allergy 2007; 92: 140-54.
19. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977-83.